Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 7, July, p. 967–972

doi: 10.17219/acem/99310

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Isothiazolopyridine Mannich bases and their antibacterial effect

Piotr Świątek1,A,B,C,D,E,F, Małgorzata Strzelecka1,B,C

1 Department of Chemistry of Drugs, Wroclaw Medical University, Poland

Abstract

Background. Infections caused by multidrug-resistant (MDR) strains, i.e., strains resistant to at least 1 antibiotic of the 3 groups of antibacterial agents, are among the most difficult to treat. New compounds with an antimicrobial action are being sought in order to avoid the complete resistance of bacteria to drugs and the spread of MDR strains.
Objectives. The aim of the research was to determine the antimicrobial activity of the new isothiazolopyridine derivatives.
Material and Methods. All chemicals used were purchased from commercial suppliers. The 1H NMR spectra were recorded on a Bruker 300 MHz NMR spectrometer. Infrared (IR) spectra were run on a Perkin-Elmer Spectrum Two UATR FT-IR spectrometer (Perkin–Elmer, Waltham, USA). Elemental analyses were carried out on a Carlo Erba NA 1500 analyzer (Carlo Erba Reagents SAS, Val de Reuil, France). Melting points were determined with a Mel-Temp II apparatus (Laboratory Devices, Holliston, USA). The bacteria panel, including Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603 (MDR), Acinetobacter baumannii ATCC 19606, Pseudomonas aeruginosa ATCC 27853, and multidrug-resistant Staphylococcus aureus ATCC 43300 (MRSA) were cultured in Muller–Hinton broth (MHB) at 37°C overnight. Colistin, Polymyxin B, Vancomycin, and Daptomycin were used as controls of bacterial inhibitors. Inhibition of bacterial growth was determined visually and was recorded at 32 μg/mL; 100% inhibition was identified.
Results. The new dimethylisothiazolopyridines were prepared by the Mannich reaction. The structures of the isothiazolopyridines were determined based on spectral data analysis, such as IR and 1H NMR. The antimicrobial screening of new compounds was performed. In the primary screen, 2 compounds showed antimicrobial activity (minimum inhibitory concentration (MIC) ≤32 μg/mL).
Conclusion. Taking into account the obtained results, it should be stated that the examined compounds did not exceed the activity of reference drugs and, therefore, further research should be carried out in the group of isothiazolopyridine derivatives.

Key words

synthesis, antibacterial agents, isothiazolopyridine

References (19)

  1. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
  2. Alanis AJ. Resistance to antibiotics: Are we in the post-antibiotic era? Arch Med Res. 2005;36(6):697–705.
  3. Ranft D, Lehwark-Yvetot G, Schaper K, Buge A. N1-Hetaryl substituted pyridine- and pyrazinecarboxamidrazones with antimycobacterial activity. Arch Pharm. 1997;330(6):169–172.
  4. Carta A, Paglietti G, Rahgar Nikookar M, Sanna P, Sechi L, Zanetti S. Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. Eur J Med Chem. 2002;37(5):355–366.
  5. Renau T, Sanchez J, Gage J, et al. Structure-activity relationships of the quinolone antibacterials against mycobacteria: Effect of structural changes at N-1 and C-7. J Med Chem. 1996;39(3):729–735.
  6. Pagani G, Borgna P, Piersimoni C, Nista D, Terreni M, Pregnolato M. In vitro anti-Mycobacterium avium activity of N-(2-hydroxyethyl)-1,2-benzisothiazol-3(2H)-one and -thione carbamic esters. Arch Pharm. 1996;329:421–425.
  7. Okachi R, Niino H, Kitaura K, et al. Synthesis and antibacterial activity of 2,2’-dithiobis(benzamide) derivatives against Mycobacterium species. J Med Chem. 1985;28(12):1772–1779.
  8. Ortega M, Montoya M, Jaso A, et al. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Pharmazie. 2001;56(3):205–207.
  9. Zani F, Incerti M, Ferretti R, Vicini P. Hybrid molecules between benzenesulfonamides and active antimicrobial benzo[d]isothiazol-3-ones. Eur J Med Chem. 2009;44(6):2741–2747.
  10. Shimizu M, Shimazaki T, Yoshida T, Ando W, Konakahara T. Synthesis of 2-alkylidene-3,1-benzoxathiin-4-ones by the Pummerer type reaction. Tetrahedron. 2012;68:3932–3936.
  11. Collier PJ, Ramsey AJ, Austin P, Gilbert PJ. Growth inhibitory and biocidal activity of some isothiazolone biocides. Appl Bacteriol. 1990;69(4):569–577.
  12. Fuller SJ, Denyer SP, Hugo WB, Pemberton D, Woodcock PM, Buckley AJ. The mode of action of l,2‐benzisothiazolin‐3‐one on Staphylococcus aureus. Lett Appl Microbiol. 1985;1(1):13–15.
  13. Collier PJ, Ramsey A, Waigh RD, Douglas KT, Austin P, Gilbert P. Chemical reactivity of some isothiazolone biocides. J Appl Bacteriol. 1990;69(4):578–584.
  14. Brickner SJ, Hutchinson DK, Barychyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39(3):673–679.
  15. Barbachyn MR, Hutchinson DK, Brickner SJ, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem. 1996;39(3):680–685.
  16. Blaskovich MA, Zuegg J, Elliott AG, Cooper MA. Helping chemists discover new antibiotics. ACS Infect Dis. 2015;1(7):285–287.
  17. Malinka W, Rutkowska M. Synthesis and anorectic activity of 2H-4,6-dimethyl-2-[(4- phenylpiperazin-1-yl)methyl]-3-oxo-2,3-dihydroisothiazolo[5,4-b]pyridine. Farmaco. 1997;52(10):595–601.
  18. Malinka W, Świątek P, Filipek B, Sapa J, Jezierska A, Koll A. Synthesis, analgesic activity and computational study of new isothiazolopyridines of Mannich base type. Farmaco. 2005;60(11–12):961–968.
  19. Malinka W, Karczmarzyk Z, Sieklucka-Dziuba M, Sadowski M, Kleinrok Z. Synthesis and in vivo pharmacology of new derivatives of isothiazolo[5,4-b]pyridine of Mannich base type. Farmaco. 2001;56(12):905-918.
© Wroclaw Medical University